Kaken will receive a prepayment of 30 million dollars from Johnson & Johnson (JNJ.US), as well as subsequent payments of up to 1.2175 billion dollars based on development progress and sales milestones.
智通财经APP has learned that Kaken Pharmaceutical recently announced that it has reached a licensing agreement with Johnson & Johnson (JNJ.US) for the global development, manufacturing, and commercialization of the STAT6 project. According to the terms of the agreement, Kaken will grant Johnson & Johnson an exclusive license to develop, manufacture, and commercialize the STAT6 project globally, including KP-723, an oral STAT6 inhibitor that is currently in preclinical development. This project aims to develop treatments for autoimmune and allergic diseases, including atopic dermatitis (AD).
Kaken will receive a $30 million upfront payment from Johnson & Johnson, as well as the potential to receive up to $1.2175 billion in milestone payments based on development progress and sales milestones. Additionally, Kaken is eligible to receive Private Equity investment from Johnson & Johnson Innovation - JJDC (the venture capital arm of Johnson & Johnson). Kaken will proceed to complete Phase 1 clinical trials for KP-723, after which Johnson & Johnson will conduct global clinical development and commercialization. Kaken will retain commercialization rights in Japan, while Johnson & Johnson will have the right to enter into a co-promotion agreement with Kaken.